Sol-Gel Technologies Ltd.
- Open
- 75.00
- Day high
- 75.00
- Day low
- 72.44
- Prev close
- 74.14
- Volume
- 10K
- Mkt cap
- $237M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.6
- P/S
- 12.8
- Yield
- —
- Per share
- —
- ▲Insiders net buying $332K over the last 3 months (3 open-market buys, 0 sales)
- 🏛Institutions accumulating (13F)
Sol-Gel Technologies Ltd. (SLGL) is a Healthcare company listed on NASDAQ. The stock is up 911% over the past year. Over the trailing 3 months, insiders filed 3 open-market buys and 0 sales (SEC Form 4).
Sol-Gel Technologies Ltd. (SLGL) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
SLGL earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 28, 2026 | $-2.86 | $-1.31 | +54.2% | $108000 | -88.0% |
| Mar 19, 2026 | $0.39 | $-1.07 | -374.4% | $7M | +0.0% |
| Nov 20, 2025 | $-2.09 | $-2.13 | -1.9% | $400000 | -93.8% |
| Aug 15, 2025 | $-0.67 | $4.17 | +722.4% | $17M | +504.0% |
| Apr 29, 2025 | $-1.10 | $-2.10 | -90.9% | $1M | -48.4% |
| Mar 26, 2025 | $-0.11 | $-0.21 | -90.8% | $278000 | -86.1% |
| Nov 15, 2024 | $-0.13 | $-0.01 | +92.3% | $5M | +168.1% |
| Aug 16, 2024 | $-0.20 | $0.07 | +135.0% | $5M | +417.4% |
| May 20, 2024 | $-0.15 | $-0.23 | -53.3% | $466000 | -49.9% |
| Mar 13, 2024 | $-0.16 | $-0.17 | -6.3% | $447000 | +65.6% |
| Nov 9, 2023 | $-0.23 | $-0.21 | +8.7% | $213000 | -21.1% |
| Aug 10, 2023 | $-0.26 | $-0.22 | +15.4% | $594000 | -61.7% |
SLGL insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 22, 2026 | Opaleye Management Inc.10 percent owner | Buy | 1,563 | $64.43 |
| May 14, 2026 | Opaleye Management Inc.10 percent owner | Buy | 1,937 | $66.87 |
| May 14, 2026 | Opaleye Management Inc.10 percent owner | Buy | 1,500 | $67.98 |
| Mar 24, 2026 | Opaleye Management Inc.10 percent owner | Buy | 5,000 | $72.00 |
| Mar 24, 2026 | Opaleye Management Inc.10 percent owner | Buy | 34,665 | $72.00 |
| Feb 18, 2026 | Opaleye Management Inc.10 percent owner | Buy | 291 | $63.00 |
| Feb 18, 2026 | Opaleye Management Inc.10 percent owner | Buy | 100 | $58.00 |
| Feb 4, 2026 | Opaleye Management Inc.10 percent owner | Buy | 100 | $58.00 |
| Jan 29, 2026 | Opaleye Management Inc.10 percent owner | Buy | 100 | $57.05 |
| Jan 23, 2026 | Opaleye Management Inc.10 percent owner | Buy | 2,173 | $56.57 |
| Jan 23, 2026 | Opaleye Management Inc.10 percent owner | Buy | 1,151 | $55.98 |
| Jan 6, 2026 | Opaleye Management Inc.10 percent owner | Buy | 2,394 | $41.92 |
| Jan 6, 2026 | Opaleye Management Inc.10 percent owner | Buy | 198 | $42.98 |
| Dec 31, 2025 | Opaleye Management Inc.10 percent owner | Buy | 22,497 | $41.99 |
| Dec 31, 2025 | Opaleye Management Inc.10 percent owner | Buy | 35,169 | $41.99 |
Source: SLGL SEC Form 4 filings, latest May 22, 2026. For informational purposes only — not investment advice.
See the full SLGL insider & 13F page →Sol-Gel Technologies Ltd. company profile
Overview
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) is an Israeli clinical-stage specialty pharmaceutical company founded in 1997 and headquartered in Ness Ziona, Israel. The company went public in February 2018 and has built its business around developing and commercializing topical dermatological treatments using a proprietary microencapsulation delivery system. Sol-Gel has successfully brought two FDA-approved products to market - Twyneo for acne treatment and Epsolay for rosacea - while maintaining a robust pipeline of additional dermatological therapies in various stages of clinical development.
Business
Sol-Gel Technologies operates in the specialty pharmaceutical sector, specifically focusing on topical dermatological treatments for skin conditions. The company's core innovation lies in its proprietary microencapsulation delivery system, which allows active pharmaceutical ingredients to be encapsulated in microscopic particles that can penetrate the skin more effectively and provide controlled, sustained release of medication. The company's primary commercial products include Twyneo, a once-daily topical cream for treating acne vulgaris (common acne), and Epsolay, a once-daily cream for papulopustular rosacea, a chronic inflammatory skin condition that causes redness and bumps on the face. Both products have completed Phase III clinical trials and received FDA approval. Acne affects millions of people worldwide, particularly teenagers and young adults, while rosacea primarily affects adults and can significantly impact quality of life. Sol-Gel's pipeline includes several other candidates in development: SGT-210 for palmoplantar keratoderma (a rare skin condition affecting palms and soles), and reformulations of existing drugs like Erlotinib, Tapinarof, and roflumilast for treating psoriasis and other dermatological conditions. The company also develops generic topical dermatological products to diversify its revenue streams. Revenue is primarily generated through product sales, with the commercial products representing the main source of income while pipeline assets represent future revenue potential.
Revenue model
Sol-Gel generates revenue primarily through product sales of its FDA-approved topical dermatological treatments. The company sells its products to dermatologists, healthcare providers, and through pharmaceutical distribution channels. Patients and their insurance providers are the ultimate paying customers, with the company typically receiving payment through the standard pharmaceutical reimbursement system. The company has established a collaboration agreement with Perrigo, a major pharmaceutical company, which likely involves licensing, manufacturing, or distribution arrangements that provide additional revenue streams through royalties or milestone payments. This partnership helps Sol-Gel leverage Perrigo's established commercial infrastructure and market reach. Several factors can significantly impact Sol-Gel's margins and profitability. Positive margin drivers include the specialty nature of dermatological treatments, which typically command higher prices than generic medications, the chronic nature of skin conditions requiring ongoing treatment, and the company's proprietary delivery technology that can provide competitive differentiation. Negative margin pressures come from the high costs of clinical trials and regulatory approval processes, competition from established dermatological companies with larger marketing budgets, potential generic competition once patents expire, and the ongoing need for significant research and development investment to maintain pipeline development. The company's small size relative to major pharmaceutical companies also limits its negotiating power with distributors and payers, potentially constraining pricing flexibility.
Competitive moat
Sol-Gel's competitive moat is moderately strong but narrow, centered primarily around its proprietary microencapsulation delivery technology and FDA-approved product portfolio. The company's microencapsulation platform provides a technological advantage that can improve drug efficacy and patient compliance through once-daily dosing, which is particularly valuable in dermatology where patient adherence is often challenging. The regulatory approval barrier provides some protection, as competitors would need to conduct their own expensive clinical trials to bring competing products to market. Sol-Gel's established relationships with dermatologists and its growing commercial presence in the topical dermatology market also create modest switching costs and brand recognition. However, the moat faces several vulnerabilities. Large pharmaceutical companies with significantly greater resources could develop competing delivery technologies or acquire similar platforms. The dermatology market is highly competitive, with established players like Johnson & Johnson, Galderma, and others having much larger marketing budgets and sales forces. Additionally, the company's patent protection is time-limited, and once patents expire, generic competition could significantly erode pricing power. The relatively small size of Sol-Gel's target markets also limits the economic moat, as the total addressable market may not be large enough to deter well-funded competitors from entering if the company demonstrates significant success.
Risks & safety
Sol-Gel presents a moderate to high-risk investment with limited margin of safety based on current financial metrics: • Cash position: $19.5 million in cash and short-term investments as of FY 2024, providing limited runway given historical burn rates • Cash burn: Negative $13.9 million operating cash flow in FY 2024, indicating continued cash consumption • Debt levels: Very low debt-to-equity ratio of 0.045, indicating minimal financial leverage risk • Solvency risk: Moderate concern given current burn rate and limited cash reserves • Valuation metrics: High price-to-book ratio of 9.0x and negative earnings make traditional value metrics challenging to assess • Current ratio: Strong at 5.9x, indicating good short-term liquidity position • Revenue volatility: Highly variable quarterly revenues ranging from $0.2M to $5.4M, indicating early commercialization stage challenges
Recent development
Based on the financial data, Sol-Gel has undergone significant strategic development over recent years. The company successfully transitioned from a pure clinical-stage entity to a commercial-stage pharmaceutical company with FDA-approved products generating revenue. This transition is evidenced by the increase in revenue from $1.6 million in FY 2023 to $11.5 million in FY 2024, representing substantial growth in commercial sales. The company has focused on building its commercial infrastructure to support the launch and marketing of Twyneo and Epsolay. The significant revenue spike in Q2 2024 to $5.4 million, followed by the company achieving positive net income and EBITDA in that quarter, suggests successful market penetration and operational leverage beginning to take effect. Sol-Gel has also maintained its commitment to pipeline development, continuing to advance SGT-210 through Phase I trials and developing additional formulations of existing drugs for dermatological applications. The collaboration with Perrigo appears to be a key strategic partnership that provides manufacturing and commercial support, allowing Sol-Gel to focus on its core competencies in drug development while leveraging a partner's operational capabilities.
SLGL company profile · for informational purposes only — not investment advice.
Track SLGL with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free